These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 21050352)
21. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer. Wadhwa VK; Weston R; Parr NJ BJU Int; 2010 Apr; 105(8):1082-8. PubMed ID: 19912210 [TBL] [Abstract][Full Text] [Related]
24. Management of metastatic hormone-sensitive prostate cancer. Bernard B; Sweeney CJ Curr Urol Rep; 2015 Mar; 16(3):14. PubMed ID: 25677237 [TBL] [Abstract][Full Text] [Related]
25. Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study. Rodrigues P; Meler A; Hering F Urol Int; 2010; 85(2):180-5. PubMed ID: 20628233 [TBL] [Abstract][Full Text] [Related]
27. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. Briot K; Paccou J; Beuzeboc P; Bonneterre J; Bouvard B; Confavreux CB; Cormier C; Cortet B; Hannoun-Lévi JM; Hennequin C; Javier RM; Lespessailles E; Mayeur D; Mongiat Artus P; Vieillard MH; Debiais F Joint Bone Spine; 2019 Jan; 86(1):21-28. PubMed ID: 30287350 [TBL] [Abstract][Full Text] [Related]
28. Risk of fracture after androgen deprivation for prostate cancer. Walsh PC J Urol; 2005 Sep; 174(3):929-30. PubMed ID: 16093991 [No Abstract] [Full Text] [Related]
29. Androgen deprivation in prostate cancer and the long-term risk of fracture. Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363 [TBL] [Abstract][Full Text] [Related]
30. [Cardiovascular risks of androgen deprivation therapy for prostate cancer]. Miller K Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571 [TBL] [Abstract][Full Text] [Related]
31. [Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer]. Izumi K; Mizokami A; Namiki M Clin Calcium; 2010 Feb; 20(2):175-81. PubMed ID: 20118508 [TBL] [Abstract][Full Text] [Related]
32. Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy. Bernat MM; Pasini J; Mareković Z Coll Antropol; 2005 Dec; 29(2):589-91. PubMed ID: 16417166 [TBL] [Abstract][Full Text] [Related]
33. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. Saylor PJ; Kaufman DS; Michaelson MD; Lee RJ; Smith MR J Urol; 2010 Jun; 183(6):2200-5. PubMed ID: 20399451 [TBL] [Abstract][Full Text] [Related]
34. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566 [TBL] [Abstract][Full Text] [Related]
35. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy. Schulman C; Irani J; Aapro M BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121 [TBL] [Abstract][Full Text] [Related]
36. Risk of fracture after androgen deprivation for prostate cancer. Shahinian VB; Kuo YF; Freeman JL; Goodwin JS N Engl J Med; 2005 Jan; 352(2):154-64. PubMed ID: 15647578 [TBL] [Abstract][Full Text] [Related]